Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial

Trial Profile

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Bendamustine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LENA-BERIT
  • Most Recent Events

    • 21 Jul 2017 This trial has been completed in Sweden (end date: 2017-04-12).
    • 11 Jul 2017 This trial has been completed in Denmark (end date: 2017-06-30).
    • 27 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top